Close

Neuros Medical Announces Key Milestones in the QUEST Pivotal Clinical Study for Chronic Post-Amputation Pain

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back

Related stories

BD Commits Expanding the Prefilled Flush...

Beckton Dickinson – BD is investing over $35mn in...

MHRA Wants Fast Patient Access to...

The medicines and healthcare products regulatory agency – MHRA...

Portable Digital Radiography for Hospitals, Ambulatory...

FUJIFILM Healthcare Americas Corporation, which happens to be a...

$12 M APAC AI For Society...

In a move that highlights the deepening commitment of Google...

Neuros Medical, Inc., a medical device company developing innovative high-frequency nerve block technology for patients with intractable post-amputation pain, announced the achievement of two milestones in its pivotal QUEST (High-FreQUEncy Nerve Block for PoST-Amputation Pain) study. QUEST is a 180-subject, randomized, double blinded, active sham controlled clinical trial that is being conducted under an Investigational Device Exemption (IDE). QUEST is designed to assess the safety & effectiveness of the Company’s Altius® High-Frequency Nerve Block system to treat intractable post-amputation pain. Post-amputation pain is a significant unmet medical need, as existing treatment options are limited, and consist primarily of opioids and gabapentinoids.

In December 2020, an independent Data Monitoring Committee successfully completed the final planned interim safety and futility analysis of 80 subjects at the 90-day primary endpoints. In addition, despite the ongoing COVID-19 pandemic, QUEST enrollment now exceeds 100 subjects, and the study is on track for completion of enrollment by the Fall of 2021.

“I wish to thank the QUEST investigators and their clinical research teams for a remarkable collective effort during this extremely challenging year,” said Leonardo Kapural MD PhD, Carolinas Pain Institute and National Principal Investigator of the QUEST study. “I believe that the Altius therapy, with its unique mechanism of action achieved with High-Frequency Nerve Block (HFNB), has great potential to become an important treatment option for post-amputation phantom and stump pain.”

“We join Dr. Kapural in expressing gratitude to the QUEST site clinical research teams for their commitment to both the study as well as to the amputee subjects whom they enrolled,” said David Veino, Neuros Chief Operating Officer. “We look forward to completing enrollment this year, a key milestone in our efforts to develop a promising treatment option for this significant unmet medical need.”

Latest stories

Related stories

BD Commits Expanding the Prefilled Flush Syringes in the US

Beckton Dickinson – BD is investing over $35mn in...

MHRA Wants Fast Patient Access to Innovative Medical Devices

The medicines and healthcare products regulatory agency – MHRA...

Portable Digital Radiography for Hospitals, Ambulatory Units

FUJIFILM Healthcare Americas Corporation, which happens to be a...

$12 M APAC AI For Society Initiative Launched by Google

In a move that highlights the deepening commitment of Google...

Subscribe

- Never miss a story with notifications

- Gain full access to our premium content

- Browse free from any location or device.

Media Packs

Expand Your Reach With Our Customized Solutions Empowering Your Campaigns To Maximize Your Reach & Drive Real Results!

– Access the Media Pack Now

– Book a Conference Call

– Leave Message for Us to Get Back